Business
Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and
About this update from Kala Bio, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nKala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the BofA Securities 2021 Healthcare Conference. Management is scheduled to participate in a Fireside Chat on Thursday, May 13, 2021 at 4:15 pm ET.\n\nTo access the webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com\n\nAbout Kala Pharmaceuticals, Inc.\nKala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of preclinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit www.kalarx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005023/en/\n\nInvestor Contact:\nHannah Deresiewicz\[email protected]\n212-362-1200\n\nSource: Kala Pharmaceuticals, Inc.","length":3036,"tagName":"div"}]